SCHEMBL15207801

SCHEMBL15207801

COc1ccc(-c2nccn3nc(Nc4ccc(OC)c(OC)c4)nc23)cn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 4/20 0.48
PTK2 Q05397 3/20 0.48
JAK3 P52333 1/20 0.48
SYK P43405 11/20 0.46
CD63 P08962 1/20 0.46
TP53 P04637 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
AURKA O14965 1/20 0.42
KIT P10721 1/20 0.42
FLT3 P36888 1/20 0.42
IRAK4 Q9NWZ3 1/20 0.42
CDK4 P11802 1/20 0.42
CCND1 P24385 1/20 0.42
CCND2 P30279 1/20 0.42
CCND3 P30281 1/20 0.42
PDGFRB P09619 1/20 0.41
PDGFRA P16234 1/20 0.41
EIF2AK4 Q9P2K8 1/20 0.41
PLK1 P53350 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15207119 0.91 JAK2 (0.47) JAK2PTK2JAK3SYKCD63
SCHEMBL15207500 0.89 SYK (0.46) JAK2SYKCD63TP53GAA
SCHEMBL15206594 0.89 SYK (0.59) JAK2SYKCD63TP53GAA
SCHEMBL21097 0.87 SYK (0.44) JAK2SYKCD63TP53GAA
SCHEMBL21816 0.87 CHEK1 (0.49) JAK2PTK2JAK3SYKCD63
SCHEMBL21119 0.87 JAK2 (0.52) JAK2PTK2JAK3GAAMAPT
SCHEMBL15207711 0.87 PIK3CA (0.45) JAK2SYKCD63TP53GAA
SCHEMBL15208269 0.86 TP53 (0.46) JAK2PTK2JAK3SYKCD63
SCHEMBL20556 0.86 JAK2 (0.50) JAK2PTK2JAK3SYKEIF2AK4
SCHEMBL30618 0.86 JAK2 (0.52) JAK2PTK2JAK3SYKTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609098-B1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-07-13 EP disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES SYK, IRAK1, ZAP70 JAK2 5/4885PTK2 367/4885JAK3 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.